NBRV - ナブリバ・セラピュ―ティクス (Nabriva Therapeutics plc) ナブリバ・セラピュ―ティクス

 NBRVのチャート


 NBRVの企業情報

symbol NBRV
会社名 Nabriva Therapeutics AG (ナブリバ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins including both intravenous and oral formulations of its lead product candidate lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications including the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is developing a formulation of lefamulin appropriate for pediatric use.   ナブリバ・セラピュ―ティクスはオ―ストリアのバイオ医薬品企業。臨床段階で、主に抗生物質プレウロムチリンに焦点を当て、感染症治療のための抗生物質の研究開発に従事する。市中感染性細菌性肺炎(CABP)の治療向け静脈点滴と経口投与薬を開発、また肺炎以外の疾患に対する有効性を研究。米国内ではペンシルベニア州に拠点を置く。本社はヴィエナ。   Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, and CONTEPO. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
本社所在地 Leberstrasse 20 Vienna 1110 AUT
代表者氏名 Daniel D. Burgess ダニエル・D・バージェス
代表者役職名 Independent Chairman of the Supervisory Board
電話番号
設立年月日 38626
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 59人
url www.nabriva.com
nasdaq_url https://www.nasdaq.com/symbol/nbrv
adr_tso
EBITDA EBITDA(百万ドル) -73.03200
終値(lastsale) 2.949
時価総額(marketcap) 196061784.891
時価総額 時価総額(百万ドル) 179.50720
売上高 売上高(百万ドル) 10.98800
企業価値(EV) 企業価値(EV)(百万ドル) 104.62120
当期純利益 当期純利益(百万ドル) -75.66100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Nabriva Therapeutics PLC - ADR revenues increased from $2.7M to $8.4M. Net loss increased 4% to $31.1M. Revenues reflect Government grants increase of 39% to $419K. Higher net loss reflects Interest income decrease of 88% to $28K (income) Interest Exp-Net of Capitalized Interest increase from $4K to $11K (expense) Other income (expense) net increase of 2% to $118K (expense).

 NBRVのテクニカル分析


 NBRVのニュース

   42 Stocks Moving in Thursday's Pre-Market Session  2020/07/16 11:22:08 Benzinga Feeds
Gainers Nabriva Therapeutics plc (NASDAQ: NBRV ) shares rose 48.9% to … Full story available on Benzinga.com
   Nabriva inks Sivextro distribution with Merck (NASDAQ:NBRV)  2020/07/15 20:11:34 Seeking Alpha
Nabriva Therapeutics (NASDAQ:NBRV) enters into an agreement with subsidiaries of Merck (NYSE:MRK) granting them exclusive distribution rights to antibiotic
   WEP Clinical entre en partenariat avec Nabriva Therapeutics pour la délivrance de XENLETA® (léfamuline) à des patients désignés  2020/07/06 21:18:00 Business Wire
LONDRES--(BUSINESS WIRE)--WEP Clinical (WEP), une société de services pharmaceutiques spécialisés, vient de signer un accord exclusif avec Nabriva Therapeutics (Nabriva) pour la délivrance de XENLETA® (léfamuline) dans le cadre d'un programme de patients désignés ou d'accès élargi. Le programme de patients désignés (NPP) est conçu pour garantir que les médecins, sous réserve de répondre aux critères d'éligibilité et d'obtenir une approbation, peuvent obtenir la formulation intraveineuse ou par
   WEP Clinical kooperiert mit Nabriva Therapeutics bei der Versorgung einzelner Patienten mit XENLETA® (Lefamulin)  2020/07/06 18:17:00 Business Wire
LONDON--(BUSINESS WIRE)--WEP Clinical (WEP), ein Unternehmen mit Schwerpunkt auf pharmazeutischen Dienstleistungen, hat mit Nabriva Therapeutics (Nabriva) einen Exklusivvertrag über die Bereitstellung von XENLETA® (Lefamulin) für einzelne Patienten bzw. auf Basis eines erweiterten Zugangs unterzeichnet. Sofern sie die erforderlichen Anforderungen erfüllen und die Berechtigung erhalten, sollen Ärzte im Rahmen des Named Patient Program (NPP) XENLETA® zur oralen oder intravenösen Behandlung anford
   WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA® (lefamulin)  2020/07/06 11:00:00 Business Wire
LONDON--(BUSINESS WIRE)--WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet availab
   42 Stocks Moving in Thursday's Pre-Market Session  2020/07/16 11:22:08 Benzinga Feeds
Gainers Nabriva Therapeutics plc (NASDAQ: NBRV ) shares rose 48.9% to … Full story available on Benzinga.com
   Nabriva inks Sivextro distribution with Merck (NASDAQ:NBRV)  2020/07/15 20:11:34 Seeking Alpha
Nabriva Therapeutics (NASDAQ:NBRV) enters into an agreement with subsidiaries of Merck (NYSE:MRK) granting them exclusive distribution rights to antibiotic
   WEP Clinical entre en partenariat avec Nabriva Therapeutics pour la délivrance de XENLETA® (léfamuline) à des patients désignés  2020/07/06 21:18:00 Business Wire
LONDRES--(BUSINESS WIRE)--WEP Clinical (WEP), une société de services pharmaceutiques spécialisés, vient de signer un accord exclusif avec Nabriva Therapeutics (Nabriva) pour la délivrance de XENLETA® (léfamuline) dans le cadre d'un programme de patients désignés ou d'accès élargi. Le programme de patients désignés (NPP) est conçu pour garantir que les médecins, sous réserve de répondre aux critères d'éligibilité et d'obtenir une approbation, peuvent obtenir la formulation intraveineuse ou par
   WEP Clinical kooperiert mit Nabriva Therapeutics bei der Versorgung einzelner Patienten mit XENLETA® (Lefamulin)  2020/07/06 18:17:00 Business Wire
LONDON--(BUSINESS WIRE)--WEP Clinical (WEP), ein Unternehmen mit Schwerpunkt auf pharmazeutischen Dienstleistungen, hat mit Nabriva Therapeutics (Nabriva) einen Exklusivvertrag über die Bereitstellung von XENLETA® (Lefamulin) für einzelne Patienten bzw. auf Basis eines erweiterten Zugangs unterzeichnet. Sofern sie die erforderlichen Anforderungen erfüllen und die Berechtigung erhalten, sollen Ärzte im Rahmen des Named Patient Program (NPP) XENLETA® zur oralen oder intravenösen Behandlung anford
   WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA® (lefamulin)  2020/07/06 11:00:00 Business Wire
LONDON--(BUSINESS WIRE)--WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet availab
   Nabriva Therapeutics (NBRV) Catches Eye: Stock Jumps 11.4%  2020/06/10 12:39:00 Zacks Investment Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
   Implied Volatility Surging for Nabriva (NBRV) Stock Options  2020/06/01 12:40:00 Zacks Investment Research
Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.
   Why Earnings Season Could Be Great for Nabriva Therapeutics (NBRV)  2020/05/07 12:32:00 Zacks Investment Research
Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Why Nabriva Therapeutics (NBRV) Stock Might be a Great Pick  2020/04/14 12:59:00 Zacks Investment Research
Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
   Will Nabriva Therapeutics Continue to Surge Higher?  2020/01/22 13:24:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ナブリバ・セラピュ―ティクス NBRV Nabriva Therapeutics plc)

 twitter  (公式ツイッターやCEOツイッターなど)